AC Immune SA share price logo

AC Immune SA

NASDAQ: ACIU

Small Cap

$2.90

+0.26

(+9.85%)

as on

AC Immune SA Stock Performance

as on August 22, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $2.65
    $2.94
    downward going graph

    8.62%

    Downside

    1.38%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.03
    $4.00
    downward going graph

    30.00%

    Downside

    37.93%

    Upside

    downward going graph

AC Immune SA share price movements today

Previous Close
$2.64
Open
$2.66
Volume
1.0M
Market Cap
$253.4M
Day's Low - High
$2.65 - $2.94
52 Week Low - High
$2.03 - $4.00

AC Immune SA Historical Returns

1 Month Return
+ 13.18 %
3 Month Return
-10.75 %
1 Year Return
+ 16.9 %
3 Year Return
-17 %
5 Year Return
-61.87 %

AC Immune SA Stock Fundamentals & Key Indicators

Check AC Immune SA market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$253.4M

EPS (TTM)

-0.66

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-4.85

Industry PE ratio

-7.283372093023256

PEG Ratio

0.21302131432609453

EBITDA

-64.4M

Revenue (TTM)

3.7M

Profit Margin

100.00%

Return On Equity TTM

-99.17%

AC Immune SA Stock Valuation

Track how AC Immune SA P/E has moved over time to understand its valuation trends.

AC Immune SA in the last 5 years

  • Overview

  • Trends

Lowest (-6.56x)

December 31, 2023

Industry (-7.28x)

December 31, 2025

Today (-3.56x)

December 31, 2025

Highest (-2.23x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -3.56x

AC Immune SA vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of AC Immune SA with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
AC Immune SA image
AC Immune SA
BUY$253.4M-61.87%-4.85100.00%NA
Revolution Medicines image
Revolution Medicines
BUY$43.7B669.3%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$128.2B154.86%29.8286.04%NA
Moderna image
Moderna
BUY$25.3B-84.24%-7.98-12.57%NA
Regeneron image
Regeneron
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for AC Immune SA Stock including INR - Dollar returns

The AC Immune SA stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

AC Immune SA investment value today

Current value as on today

₹1,49,213

Returns

₹49,213

(+49.21%)

Returns from AC Immune SA Stock

₹36,150 (+36.15%)

Dollar Impact

₹13,063 (+13.06%)

Analyst Recommendation on AC Immune SA Stock

Based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'BUY' rating for AC Immune SA. Average target price of $8.57

AC Immune SA Share Price Target

Get share price movements and forecasts by analysts on AC Immune SA.

What analysts predicted

66.16%UPSIDE

Target Price

$8.57

Current Price

$2.9

Analyzed by

1 Analysts

Target

$8.57

AC Immune SA target price $8.57, a slight upside of 66.16% compared to current price of $2.9. According to 1 analysts rating.

Indian Investors' Interest in AC Immune SA Stock

Search interest for AC Immune SA Stock has increased by 4% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:4% versus previous 30 day period

AC Immune SA Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
14
-
0
25
1
0
1
0
0
1
Gross Profit
14
-
0
25
1
0
1
0
0
1
Operating Income
-3
-20
-20
7
-18
-19
-19
-16
-14
-14
EBITDA
-4
-17
-22
6
-15
-18
-20
-15
-13
-14
Interest Expense
0
0
0
0
0
0
0
-
0
0
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-4
-17
-22
5
-15
-19
-21
-15
-14
-14
Income Tax Expense
0
-
-
-
0
-
-
-
-
-
Net Income
-4
-17
-22
5
-15
-19
-21
-15
-14
-14
Net Profit Margin
100.00%
0.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%

AC Immune SA Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
20
7
110
15
-
3
14
27
3
Gross Profit
-12
-37
60
-44
-
3
-39
-35
3
Operating Income
-22
-49
44
-61
-79
-70
-53
-52
-68
EBITDA
-22
-49
45
-59
-70
-68
-51
-48
-67
Interest Expense
0
0
1
0
0
0
0
0
0
Depreciation
0
0
1
1
2
2
2
2
2
Income Before Tax
-26
-50
45
-61
-72
-70
-54
-50
-70
Income Tax Expense
0
-
-
-
0
0
0
0
-
Net Income
-26
-50
45
-61
-72
-70
-54
-50
-70
Net Profit Margin
-61.26%
-515.47%
54.34%
-285.50%
0.00%
100.00%
-268.93%
-129.12%
100.00%

AC Immune SA Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-4
-17
-22
5
-15
-19
-21
-15
-14
-18
Operating Cash Flow
-16
1
73
-14
5
-18
-15
-18
-16
-
Investing Cash Flow
23
-23
-75
-2
-3
3
23
20
15
-
Financing Cash Flow
41
0
0
0
0
0
0
0
0
-
Change in Cash
46
-21
-5
-19
3
-16
5
2
0
-9

AC Immune SA Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-26
-50
45
-61
-72
-70
-54
-50
-67
Operating Cash Flow
-22
-44
55
-59
-65
-73
-60
65
-66
Investing Cash Flow
-1
-32
-66
28
-53
23
65
-105
60
Financing Cash Flow
0
109
49
0
40
-1
43
-1
0
Change in Cash
-27
32
37
-32
-78
-50
46
-42
-4

Mutual Funds that own AC Immune SA Stock

Check out the Mutual Funds with significant holdings in AC Immune SA.

Funds
Holdings
Shares Held
DFA INVESTMENT DIMENSIONS GROUP INC
0.103446%
105281
Fidelity Concord Street Trust
0.062492%
63601

Global Institutional Holdings in AC Immune SA

Funds
Holdings
iShares
0.6%
Dimensional
0.14%
Invesco
0.01%
ProShares
0%

AC Immune SA News & Key Events

  • img

    Today's Timeline - 20 August

    Thu, 10:10 PM

    -

    AC Immune's 2026 loss estimates narrowed from 84 cents to 60 cents; shares down 17.9% year to date.

Insights on AC Immune SA

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 338.0K → 15.11M (in $), with an average increase of 81.2% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ACIU stock has moved up by 16.5%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -14.80M → 1.87M (in $), with an average increase of 889.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 466.0% return, outperforming this stock by 431.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 586.8% return, outperforming this stock by 592.0%

About AC Immune SA

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
OrganisationAC Immune SA
HeadquartersBuilding B, Lausanne, Switzerland, 1015
IndustryBiotechnology
CEODr. Martin Zugel M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of AC Immune SA

Name

Title

Dr. Oliver Sol M.D.

VP & Head of Clinical Development

Dr. Julien Rongere Ph.D.

Senior Vice President of Regulatory Affairs & Quality Assurance

Dr. Francesca Capotosti

Senior Vice President of Research

Dr. Gary Anthony Waanders Ph.D.

Senior VP of Investor Relations & Corporate Communications

Mr. Piergiorgio Donati

Chief Operating Officer

Dr. Martin Zugel M.D., Ph.D.

Interim CEO & Chairman of the Board

Dr. Matthias Maurer Ph.D.

Senior VP & General Counsel

Mr. Mark Danton

Executive Vice President of Information Systems & Artificial Intelligence

Dr. Günther Staffler Ph.D.

Executive Vice President of Development

Mr. Christopher Roberts

CFO & VP of Finance

FAQs

What is AC Immune SA share price today?

AC Immune SA share price today is $2.90 as on at the close of the market. AC Immune SA share today touched a day high of $2.94 and a low of $2.65.

What is the 52 week high and 52 week low for AC Immune SA share?

AC Immune SA share touched a 52 week high of $4.00 on and a 52 week low of $2.03 on . AC Immune SA stock price today i.e. is closed at $2.90,which is 27.50% down from its 52 week high and 42.86% up from its 52 week low.

What is AC Immune SA's market capitalisation today?

AC Immune SA market capitalisation is $0.00T as on .

How to invest in AC Immune SA Stock (ACIU) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for AC Immune SA on INDmoney app. Click on Buy button. You can invest as low as $1.5 in AC Immune SA Shares that will get you 0.5172 shares as per AC Immune SA share price of $2.90 per share as on August 22, 2026 at 8:45 am IST.

What is the minimum amount required to buy AC Immune SA Stock (ACIU) from India?

Indian investors can start investing in AC Immune SA (ACIU) shares with as little as ₹95.71 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.10 in AC Immune SA stock (as per the Rupee-Dollar exchange rate as on ). Based on AC Immune SA share’s latest price of $2.90 as on August 22, 2026 at 8:45 am IST, you will get 3.4483 shares of AC Immune SA. Learn more about fractional shares .

What are the returns that AC Immune SA has given to Indian investors in the last 5 years?

AC Immune SA stock has given -61.87% share price returns and 29.17% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?